Safety
hyperphosphatemia, Cancer
ADVERSE EVENT, HYPERPHOSPHATEMIA, EYE, CANCER
Safety and tolerability were assessed by monitoring the frequency and duration of AEs, measuring vital signs, conducting 12‐lead electrocardiograms, and performing comprehensive eye examinations and physical examinations. Eye examinations were performed once every 3 cycles ±14 days and as clinically indicated, starting on Cycle 3. Severity of AEs was assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 4.03 Grades 1 through 4. Severity of hyperphosphatemia is not included in CTCAE version 4.03 and was graded as follows: Grade 1 is asymptomatic or with mild symptoms requiring clinical or diagnostic observations only; Grade 2 requires minimal, local, or noninvasive intervention, and limits age‐appropriate activities of daily living; Grade 3 is severe or medically significant hyperphosphatemia that is not immediately life‐threatening, for which hospitalization or prolongation of hospitalization is indicated; Grade 4 hyperphosphatemia requires urgent intervention and is associated with life‐threatening consequences.